Verona Pharma plc Financials

Market Capitalization $7.78 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-42.37
Forward PE	-326.89
Price to Sales TTM	$65.62
Price to Book MRQ	$36.82
Enterprise to Revenue	580.46
Enterprise to EBITDA	-514.85

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-138.31%
Operating Margin	-13.53%
Return on Assets TTM	-20.64%
Return on Equity TTM	-72.61%

Income Statement

Revenue TTM	$118,535,000
Revenue per Share TTM	$1.44
Quarterly Revenue Growth	108.04%
Gross Profit TTM	$112,546,000
EBITDA	$-133,641,000
Net Income to Common TTM	$-163,943,008
Diluted EPS TTM	$-2.00
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$401,415,008
Total Cash per Share MRQ	$0.55
Total Debt MRQ	$
Total Debt to Equity MRQ	107.63
Current Ratio MRQ	8.86
Book Value per Share MRQ	$2.49

Cash Flow

Operating Cash Flow TTM	$-120,154,000
Levered Free Cash Flow TTM	$-69,146,248

VRNA Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	677,008,254
Float Shares	550,912,736
Avg 10 Volume	983,050
Avg 30 Volume	None
Shares Short	8,415,794
Short Ratio	6.19
Short % of Shares	10.31%
% Held by Insiders	10.40%
% Held by Institutions	90.98%

Stock Price Summary

Beta	0.22
Fifty Two Week Low	$15.56
Fifty Two Week High	$99.01
Fifty Two Week Change	82.40%
Day 50 MA	$79.38
Day 200 MA	$55.57

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date